Novel combinatorial therapies involving leptin: Opportunities for mechanistic advances and therapeutic translation in human diseases

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Standard

Novel combinatorial therapies involving leptin : Opportunities for mechanistic advances and therapeutic translation in human diseases. / Müller, Timo D.; Clemmensen, Christoffer; Finan, Brian; Dimarchi, Richard D.; Tschöp, Matthias H.

Leptin: Regulation and Clinical Applications. Springer, 2015. p. 267-279.

Research output: Chapter in Book/Report/Conference proceeding › Book chapter › Research › peer-review

Harvard

Müller, TD, Clemmensen, C, Finan, B, Dimarchi, RD & Tschöp, MH 2015, Novel combinatorial therapies involving leptin: Opportunities for mechanistic advances and therapeutic translation in human diseases. in Leptin: Regulation and Clinical Applications. Springer, pp. 267-279. https://doi.org/10.1007/978-3-319-09915-6_21

APA

Müller, T. D., Clemmensen, C., Finan, B., Dimarchi, R. D., & Tschöp, M. H. (2015). Novel combinatorial therapies involving leptin: Opportunities for mechanistic advances and therapeutic translation in human diseases. In Leptin: Regulation and Clinical Applications (pp. 267-279). Springer. https://doi.org/10.1007/978-3-319-09915-6_21

Vancouver

Müller TD, Clemmensen C, Finan B, Dimarchi RD, Tschöp MH. Novel combinatorial therapies involving leptin: Opportunities for mechanistic advances and therapeutic translation in human diseases. In Leptin: Regulation and Clinical Applications. Springer. 2015. p. 267-279 https://doi.org/10.1007/978-3-319-09915-6_21

Author

Müller, Timo D. ; Clemmensen, Christoffer ; Finan, Brian ; Dimarchi, Richard D. ; Tschöp, Matthias H. / Novel combinatorial therapies involving leptin : Opportunities for mechanistic advances and therapeutic translation in human diseases. Leptin: Regulation and Clinical Applications. Springer, 2015. pp. 267-279

Bibtex

@inbook{fe4daa7923744320bb1d60b7a967fee5,
title = "Novel combinatorial therapies involving leptin: Opportunities for mechanistic advances and therapeutic translation in human diseases",
abstract = "The escalating prevalence of obesity represents an increasing socioeconomic burden for international health care systems. So far, pharmacological anti-obesity therapies were overall incapable of tackling the obesity epidemic. The development of novel pharmacotherapies that improve systems metabolism in a safe yet efficient manner is of increasing global priority. Novel polypharmacological approaches, that are based either on adjunctive administration of several hormones or on combination of several hormones into single molecules, have shown a remarkable success in reversing metabolic alterations associated with the metabolic syndrome. The aim of this chapter is to summarize recent advances in preclinical and clinical approaches that employ novel combinations of leptin and other drugs, hormones, and biogenic peptides.",
keywords = "GIP, GLP-1, Glucagon, Leptin, Polypharmacotherapy",
author = "M{\"u}ller, {Timo D.} and Christoffer Clemmensen and Brian Finan and Dimarchi, {Richard D.} and Tsch{\"o}p, {Matthias H.}",
note = "Publisher Copyright: {\textcopyright} Springer International Publishing Switzerland 2015.",
year = "2015",
month = jan,
day = "1",
doi = "10.1007/978-3-319-09915-6_21",
language = "English",
isbn = "9783319099149",
pages = "267--279",
booktitle = "Leptin",
publisher = "Springer",
address = "Switzerland",

}

RIS

TY - CHAP

T1 - Novel combinatorial therapies involving leptin

T2 - Opportunities for mechanistic advances and therapeutic translation in human diseases

AU - Müller, Timo D.

AU - Clemmensen, Christoffer

AU - Finan, Brian

AU - Dimarchi, Richard D.

AU - Tschöp, Matthias H.

N1 - Publisher Copyright: © Springer International Publishing Switzerland 2015.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - The escalating prevalence of obesity represents an increasing socioeconomic burden for international health care systems. So far, pharmacological anti-obesity therapies were overall incapable of tackling the obesity epidemic. The development of novel pharmacotherapies that improve systems metabolism in a safe yet efficient manner is of increasing global priority. Novel polypharmacological approaches, that are based either on adjunctive administration of several hormones or on combination of several hormones into single molecules, have shown a remarkable success in reversing metabolic alterations associated with the metabolic syndrome. The aim of this chapter is to summarize recent advances in preclinical and clinical approaches that employ novel combinations of leptin and other drugs, hormones, and biogenic peptides.

AB - The escalating prevalence of obesity represents an increasing socioeconomic burden for international health care systems. So far, pharmacological anti-obesity therapies were overall incapable of tackling the obesity epidemic. The development of novel pharmacotherapies that improve systems metabolism in a safe yet efficient manner is of increasing global priority. Novel polypharmacological approaches, that are based either on adjunctive administration of several hormones or on combination of several hormones into single molecules, have shown a remarkable success in reversing metabolic alterations associated with the metabolic syndrome. The aim of this chapter is to summarize recent advances in preclinical and clinical approaches that employ novel combinations of leptin and other drugs, hormones, and biogenic peptides.

KW - GIP

KW - GLP-1

KW - Glucagon

KW - Leptin

KW - Polypharmacotherapy

UR - http://www.scopus.com/inward/record.url?scp=84944542663&partnerID=8YFLogxK

U2 - 10.1007/978-3-319-09915-6_21

DO - 10.1007/978-3-319-09915-6_21

M3 - Book chapter

AN - SCOPUS:84944542663

SN - 9783319099149

SP - 267

EP - 279

BT - Leptin

PB - Springer

ER -

ID: 347798086